Country for PR: China
Contributor: PR Newswire Asia (China)
Friday, April 09 2021 - 00:35
Shanghai Genechem Co., Ltd. (Genechem) Announces appointment of Dr. Eric Rowinsky and Dr. Manuel Hidalgo to Scientific Advisory board, and abstract presentation at AACR 2021 on Claudin 6 Ab and K-Ras TCR-T
SHANGHAI, April 8, 2021 /PRNewswire-AsiaNet/ --

Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel 
target discovery and development of novel therapeutics, today announced the 
appointment of Dr. Eric Rowinsky, President and Executive Chairman of the Board 
of Rgenix, Inc., and Dr. Manuel Hidalgo, Chief of Hematology and Medical 
Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell 
Medical Center, to its Scientific Advisory Board. Drs. Rowinsky and Hidalgo 
will bring their strong expertise in translational and clinical development to 
support Genechem's mission to bring its innovative pipeline to global markets 
through novel target discovery, early development in China, and global 

Genechem also announces that it will present two abstracts at AACR 2021, on an 
antibody against Claudin 6, and a TCR-T therapy against K-Ras mutations.  

"We are excited to welcome Drs. Rowinsky and Hidalgo, global leaders in 
biopharma industry and translational/clinical development, to our SAB, as we 
position Genechem to collaborate with cancer centers and biopharmaceutical 
companies globally to advance development of its innovative pipeline developed 
on our Good Research Practice (GRP) platform, leveraging CHAMP antibody 
discovery platform and Cell Therapy Discovery platform", commented Yueqiong 
Cao, Founder and CEO of Genechem.

"Genechem has built an innovative preclinical pipeline over the last five 
years, building on almost 20 years of partnership with research Oncologists in 
China, and I look forward to contributing my expertise to their mission of 
bringing innovative medicine to patients and partners globally. I am also 
impressed by their vision and global caliber management team, which I will 
enjoy working with", Dr. Rowinsky remarked. 

Dr. Rowinsky is currently serving on the Board of Directors for Biogen and as 
President and Executive Chairman of RGenix, Inc. Dr. Rowinsky has also been the 
Chief Scientific Officer of Clearpath Development Co., which rapidly advances 
development stage therapeutic assets to pre-defined human proof-of-concept 
milestones. Dr. Rowinsky was the Head of Research and Development and Chief 
Medical Officer of Stemline Therapeutics, Inc., a biotechnology company 
focusing on the discovery and development of therapeutics targeting cancer stem 
cells. Dr. Rowinsky has also been an Adjunct Professor of Medicine at New York 
University and has been an independent consultant from 2010-2019. Prior to 
that, he was the Chief Executive  Officer of Primrose Therapeutics, Inc., a 
start-up biotechnology company focusing on the development of therapeutics for 
polycystic kidney disease. From 2005 to December 2009 he served as the Chief 
Medical Officer and Executive Vice President of ImClone Systems Incorporated, a 
life sciences company. From 1996 to 2004 Dr. Rowinsky held several positions at 
the Cancer Therapy & Research Center's Institute for Drug Development, 
including Director of the Institute and Director of Clinical Research. During 
that time, he held the SBC Endowed Chair for Early Drug Development and was 
Clinical Professor of Medicine at the University of Texas Health Science Center 
at San Antonio. From 1988 to 1996 Dr. Rowinsky was an associate professor of 
oncology at the Johns Hopkins School of Medicine and on the staff of the Johns 
Hopkins Hospital. Dr. Rowinsky is also a member of the Boards of Directors of 
Fortress Biotech Inc., Purple Biotech Ltd. and Verastem, Inc., all of which are 
biopharmaceutical companies.

"As a clinical oncologist involved in drug discovery and clinical trials, I'm 
excited to bring my expertise to Genechem and help advance its antibody and 
cell therapy platforms. I am pleased to support Genechem's global efforts in 
advancing scientific understanding of cancer and addressing clinical unmet 
needs, in particular in solid tumors," said Dr. Hidalgo, who receives an 
honorarium for participation on Genechem's SAB.

Manuel Hidalgo, M.D., currently the Chief of the Division of Hematology 
and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill 
Cornell Medical Center. He is also the Hugh E. Luckey Distinguished Professor 
of Medicine and a senior member of the Sandra and Edward Meyer Cancer Center at 
Weill Cornell Medicine. Dr. Hidalgo received his MD degree from the University 
of Navarra in Pamplona, Spain in 1992 and a Ph.D. degree from University 
Autonoma of Madrid in 1997. He trained in medicine and medical oncology at 
Hospital ¨12 de Octubre¨ in Madrid and at the University of Texas Health 
Science Center in San Antonio. He also completed a fellowship program in 
anticancer drug development at the Institute of Drug Development in San 
Antonio, TX. Prior to this position he served as an Assistant Professor of 
Medicine at the Division of Hematology and Oncology at the University of Texas 
Health Science Center in San Antonio. In 2001, Dr. Hidalgo relocated to Johns 
Hopkins University to be Director of the Gastrointestinal Oncology Program at 
the Kimmel Comprehensive Cancer Center at Johns Hopkins and Associate Professor 
of Oncology. In 2009 he became Director of the Clinical Research Program at the 
Spanish National Cancer Center and Vice director of Translational Research in 
2011. In 2015 he became the Chief of the Division of Hematology and Oncology 
and Director of the Rosenberg Clinical Cancer Center at the Beth Israel 
Deaconess Medical Center in Boston. He was also the Theodore W. and Evenly G. 
Berenson Professor of Medicine at Harvard Medical School. His main focus of 
research has been new drug development in pancreatic cancer. His group 
popularized the use of Avatar mouse models for cancer research and recently 
contributed to the development and approval of nab-paclitaxel for pancreatic 
cancer treatment. His current work focuses on strategies for personalized 
medicine and immunotherapy in pancreatic cancer.

About Shanghai Genechem Co., Ltd. (Genechem)

Genechem is a leading innovation research company focused on target 
discovery/validation, development of antibody and cell therapy products against 
novel targets, and partnership globally to maximize its portfolio. Founded in 
2002, now with over 500 employees, Genechem works closely with Research 
Oncologists to translate clinical research into therapeutics addressing high 
clinical unmet needs, leveraging its strong network of Research Oncologists in 
over 300 hospitals and Good Research Practice (GRP platform) which includes 
comprehensive RNAi library, tools including genetic typing, bioinformatic 
analysis, genetic manipulation, as well as SOP and project management systems. 
For more information, visit 


Dr. Tong Zhang
Chief Business Officer
Shanghai Genechem Co., Ltd

SOURCE  Shanghai Genechem Co., Ltd. (Genechem)